蝌蚪网

关注我们的社交群

A*STAR 新闻

新科研社交媒体平台

关注新科研的最新消息、观看我们的科学视频及其他更多精彩的内容等!

astar avatar waving


   

了解新科研

查看以下信息图表,欲知更多有关我们科学研发和技术创新.

A*STAR Stickers
下载新科研WhatsApp 张贴纸

下载新科研电报贴纸
新科研最新贴文

From 蝌蚪网to the world: Where Fortitude Kit has been deployed globally

Close collaboration between scientists and the public health community have enabled the Fortitude Kit diagnostic to be quickly developed and deployed in 蝌蚪网hospitals to detect the SARS-CoV-2 virus that causes COVID-19. From February, Fortitude Kit has been in routine use in 13 蝌蚪网hospitals and labs, public and private. Currently, it is also used by healthcare professionals globally to fight the novel coronavirus pandemic. To date, the kits have been deployed in more than 20 countries globally. See map below for where Fortitude Kit is now in use.

COVID-19 : Where Fortitude Kit has been deployed globally

The kit was co-developed by A*STAR’s Experimental Drug Development Centre (EDDC), Bioinformatics Institute (BII), and the Department of Laboratory Medicine at Tan Tock Seng Hospital (TTSH). The Diagnostics Development (DxD) Hub supported the optimisation, verification, validation and production of these tests. DxD Hub is a national initiative led by A*ccelerate, the commercialisation arm of A*STAR.

The evolution of the SARS-CoV-2 virus is continually tracked by Dr Sebastian Maurer-Stroh, Deputy Executive Director (Research) of BII through the Global Initiative on Sharing all Influenza Data (GISAID) platform, which promotes the international sharing of all influenza virus sequences. This ensures the continual high accuracy of the Fortitude Kit in detecting the virus in COVID-19 patients. This also enables A*STAR to update or upgrade the Fortitude Kit on an ongoing basis to stay ahead of virus mutations.

A*STAR has transferred the technology know-how to biotechs through a non-exclusive license, to scale-up, and manufacture the diagnostic kits to further fulfil local and international demand.

Wall Street Journal Online: How diagnostic kits work

In an interview with the Wall Street Journal, Dr Sidney Yee, CEO of the DxD Hub shared that Reverse Transcription-Polymerase Chain Reaction (RT-PCR) is the gold standard method to detect the presence of pathogens. She highlighted that effective virus screening is also dependent on many factors such as transportation of patient samples to the lab, and the lab infrastructure to run the tests.